Compile Data Set for Download or QSAR
Report error Found 344 of affinity data for UniProtKB/TrEMBL: P26664
TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287983(US10087167, Compound 1001)
Affinity DataEC50:  45.4nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287985(US10087167, Compound 2001)
Affinity DataEC50:  550nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287986(US10087167, Compound 3001)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287988(US10087167, Compound 3002)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287989(US10087167, Compound 3003)
Affinity DataEC50:  25.2nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287990(US10087167, Compound 4001)
Affinity DataEC50: >1.00E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287991(US10087167, Compound 4002)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287992(US10087167, Compound 4003)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287994(US10087167, Compound 4004)
Affinity DataEC50:  1.69E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287995(US10087167, Compound 4005)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287997(US10087167, Compound 4006)
Affinity DataEC50:  550nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287998(US10087167, Compound 4007)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM287999(US10087167, Compound 4008)
Affinity DataEC50:  107nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288000(US10087167, Compound 4009)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288001(US10087167, Compound 4010)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288002(US10087167, Compound 4011)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288003(US10087167, Compound 4012)
Affinity DataEC50:  27.1nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288004(US10087167, Compound 4013)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288005(US10087167, Compound 4014)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288006(US10087167, Compound 4015)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288007(US10087167, Compound 4016)
Affinity DataEC50:  84.8nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288008(US10087167, Compound 4017)
Affinity DataEC50: >1.00E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288009(US10087167, Compound 4018)
Affinity DataEC50:  550nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288010(US10087167, Compound 4019)
Affinity DataEC50: >1.00E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288011(US10087167, Compound 4020)
Affinity DataEC50:  45nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288012(US10087167, Compound 4021)
Affinity DataEC50: >1.00E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288013(US10087167, Compound 4022)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288014(US10087167, Compound 4023)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288015(US10087167, Compound 4024)
Affinity DataEC50:  76.5nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288016(US10087167, Compound 4025)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288017(US10087167, Compound 4026)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM288018(US10087167, Compound 4027)
Affinity DataEC50: >1.00E+3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241823(US9416139, 2 | US9416139, 1)
Affinity DataEC50:  0.760nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241823(US9416139, 2 | US9416139, 1)
Affinity DataEC50:  1.28nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241825(US9416139, 3)
Affinity DataEC50:  0.537nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241826(US9416139, 4)
Affinity DataEC50:  0.0890nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241827(US9416139, 5)
Affinity DataEC50:  0.0780nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241828(US9416139, 6)
Affinity DataEC50:  0.109nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241829(US9416139, 7)
Affinity DataEC50:  0.210nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241830(US9416139, 8)
Affinity DataEC50:  0.982nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241831(US9416139, 9)
Affinity DataEC50:  0.439nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241832(US9416139, 11 | US9416139, 10)
Affinity DataEC50:  1.27nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241832(US9416139, 11 | US9416139, 10)
Affinity DataEC50:  0.0680nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241834(US9416139, 12)
Affinity DataEC50:  0.380nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241835(US9416139, 13)
Affinity DataEC50:  2.07nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241836(US9416139, 14)
Affinity DataEC50:  0.884nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241837(US9416139, 15)
Affinity DataEC50:  0.206nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241838(US9416139, 16)
Affinity DataEC50:  0.0890nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241839(US9416139, 17)
Affinity DataEC50:  0.0230nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetGenome polyprotein [1973-2420](HCV)
Sunshine Lake Pharma

US Patent
LigandPNGBDBM241840(US9416139, 18)
Affinity DataEC50:  0.326nMAssay Description:The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

Displayed 1 to 50 (of 344 total ) | Next | Last >>
Jump to: